EP Patent

EP2204168A1 — Once daily formulations of tetracyclines

Assigned to Supernus Pharmaceuticals Inc · Expires 2010-07-07 · 16y expired

What this patent protects

Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory dis…

USPTO Abstract

Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

Drugs covered by this patent

Patent Metadata

Patent number
EP2204168A1
Jurisdiction
EP
Classification
—
Expires
2010-07-07
Drug substance claim
No
Drug product claim
No
Assignee
Supernus Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.